Boston Scientific Announces Positive Results from SIMPLAAFY Clinical Trial

Boston Scientific reported positive results from the SIMPLAAFY trial, which randomized 1,857 patients at 86 U.S. sites after WATCHMAN FLX Pro implantation. Aspirin alone and reduced-dose NOAC alone were noninferior to dual anti-platelet therapy (DAPT), with less bleeding and equivalent ischemic stroke rates. At 45 days, reduced-dose NOAC was also associated with fewer device-related thrombi than DAPT. The findings support simpler post-implant treatment for patients with non-valvular atrial fibrillation.